{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-058762","form_type":"8-K","ticker":"IPSC","cik":"0001850119","company_name":"Century Therapeutics, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.224366+00:00","generated_at":"2026-06-15T04:52:49.671184+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Century Therapeutics Q1 net loss $31.3M; cash $334.8M; CNTY-101 data expected by year end","bullets":["Q1 net loss $31.3M vs $37.5M prior year; R&D expenses $24.9M, G&A $8.9M.","Cash, equivalents, investments $334.8M as of March 31, 2023; cash runway into 2026.","CNTY-101 Phase 1 ELiPSE-1 trial ongoing; initial data from Schedule A expected by year end 2023.","FY2023 GAAP operating expense guidance $135-145M; non-cash stock comp $12-17M.","Leadership: Greg Russotti interim CEO (since March), Michael Diem CFO, Hy Levitsky President of R&D."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-058762","json":"https://secwatch.observer/filing/0001104659-23-058762.json","markdown":"https://secwatch.observer/filing/0001104659-23-058762.md","text":"https://secwatch.observer/filing/0001104659-23-058762.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850119/000110465923058762/0001104659-23-058762-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850119/000110465923058762/tm2315313d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:52:49.671184+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2f7c179cba340f015a111e4ca22403aacab7f6dc","claim":"Century Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: revenue $1.7 million. Guidance reaffirmed.","evidence_excerpt":"of $122.1 million). · Collaboration Revenue: Collaboration revenue generated through the Company’s collaboration, option and license agreement with Bristol-Myers Squibb was $1.7 million for the three months ended March 31, 2023, compared to $1.1 million for the same period in 2022. · Research and Development (R&D) expenses : R&D expenses were $24.9 million for","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850119/000110465923058762/0001104659-23-058762-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$1.7 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}